Peptide · Agonist of insulin receptor (INSR) · developed by Mannkind
TI Inhalation Powder is an inhaled insulin formulation given immediately before a meal for prandial glucose control.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00747006 | Phase 2 | Diabetes Mellitus, Type 2 | Terminated | MNKD |
| NCT01982604 | Phase 1 | Healthy Volunteers | Completed | MNKD |
| NCT00757367 | Phase 1 | Healthy Subjects | Completed | MNKD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Healthy SubjectsHealthy Volunteers
Updated Oct 18, 2026. Something wrong or missing? Report it on the MNKD page.
See MNKD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MNKD catalysts and pipeline →